UniSyn Fibertec has completed a staged $3.5 million equityfinancing to develop its mammalian cell culture business. TheSan Diego company said it will receive the final $500,000 of thefinancing in the next few weeks. UniSyn was created bySynbiotics Corp. (NASDAQ:SBIO), which will continue to hold a48 percent stake. Other UniSyn investors are H&Q LondonVentures, Ventana Partnership III and 10 private investors.

(c) 1997 American Health Consultants. All rights reserved.